• Pulmonary hypertension, part 3: Early therapies and vascular physiology

  • Mar 25 2025
  • Length: 48 mins
  • Podcast

Pulmonary hypertension, part 3: Early therapies and vascular physiology

  • Summary

  • In this episode, we dive into the early therapies and how our understanding of vascular physiology drastically changed the management of pulmonary hypertension.

    • Intro 0:12
    • In this episode 0:18
    • Recap of part 1 & 2 0:31
    • What part 3 is about 2:31
    • WHO conference in 1975: Treating pulmonary hypertension 3:48
    • The Discovery of Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Part 1 5:20
    • Epoprostenol 6:18
    • Prostacyclin 10:37
    • Endothelin antagonists 11:41
    • Phosphodiesterase type 5 (PDE5) inhibitors 14:08
    • Interaction of nerves and blood vessels 15:06
    • The Soups VS the Sparks 17:36
    • A dreamed experiment 19:06
    • Acetylcholine 23:23
    • Enter “the calabar bean” 24:45
    • Acetylcholine and vasodilation: 1976 26:01
    • Rabbit aorta 27:45
    • Nitric oxide 29:38
    • Why are we using nitric oxide to treat pulmonary hypertension? 31:31
    • Tachyphylaxis 33:48
    • TNT factories 35:09
    • Nitrous oxide and tachyphylaxis 36:52
    • Pfizer in the 1980s 38:06
    • Understanding the trigger of pulmonary hypertension 40:53
    • PDE5 and nitric oxide and pulmonary hypertension 43:07
    • The end of the ripping yarns 44:20
    • Coming up in part 4 46:17
    • Thanks for listening 47:29

    We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

    References:
    Bernard C. C R Soc Biol. 1851;3:163-164.
    Furchgott RF, et al. Nature. 1980;doi:10.1038/288373a0.
    Galiè N, et al. N Engl J Med. 2005;doi:10.1056/NEJMoa050010.
    Ghofrani HA, et al. Nat Rev Drug Discov. 2006;doi:10.1038/nrd2030.
    Giordano D, et al. Biochim Biophys Acta. 2001;doi:10.1016/s0167-4889(01)00086-6.
    Guthrie F. Q J Chem Soc. 1859;doi:10.1039/QJ8591100245.
    Higenbottam T, et al. Lancet. 1984;doi:10.1016/s0140-6736(84)91452-1.
    Marsh N, et al. Clin Exp Pharmacol Physiol. 2000;doi:10.1046/j.1440-1681.2000.03240.x.
    Montastruc JL, et al. Clin Auton Res. 1996;doi:10.1007/BF02281906.
    Nejad SH, et al. Future Cardiol. 2024;doi:10.1080/14796678.2024.2367390.
    Tansey EM. C R Biol. 2006;doi:10.10116/j.crvi.2006.03.012.
    Warren JV. Trans Am Clin Climatol Assoc. 1988;99:10-6.

    Disclosures: Brown reports no relevant financial disclosures.

    Show More Show Less

What listeners say about Pulmonary hypertension, part 3: Early therapies and vascular physiology

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.